Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
Stopped Study terminated due to a safety event which rendered the risk-benefit profile in NASH to no longer be adequately favorable
Conditions
- Nonalcoholic Steatohepatitis
Interventions
- DRUG: SGM-1019
- DRUG: Placebo
Sponsor
Second Genome